Pacira BioSciences, Inc.

Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Nov. 5, 2026 /PRNewswire/ -- Viatris Inc.  (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results. Executive Commentary "Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business," said Scott A.

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper Sadeh encourages Pacira shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Pacira and its board of directors violated t.

PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 30, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the accompanying Letter of Transmittal (the "Letter of Transmittal" and, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merger, dated Oct. 8, 2026, by and among Viatris, Purchaser and Pacira (as it may be amended or supplemented from time to time, the "Merger Agreement").